|
|
|
|
The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Cystic Fibr
From the Departments of Respiratory Medicine (Drs.Amin and Ratjen), and Child Health and Evaluative Services (Dr. Dupuis), The Hospital for Sick Children, The University of Toronto, Toronto, ON, Canada; and the Division of Respiratory...
|
|
|
Calixa Initiates Phase 2 Clinical Trial For UTI
CXA-101, a potential treatment for serious bacterial infections in hospitalized patients Calixa has initiated a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections (UTI).CXA-101 is a parenteral...
|
|
|
iP. aeruginosa/i infection predicts disease severity in COPD
MedWire News: Infection with Pseudomonas aeruginosa is common in patients presenting with acute exacerbations of chronic obstructive pulmonary disease (COPD) and predicts more severe disease, say researchers.It has been suggested...
|
|
|
Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients Wit
Calixa Therapeutics Inc.today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in...
|
|
|
Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients wit
SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc.today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral...
|
|
|
European CHMP Adopts Positive Opinion for Aztreonam Lysine
Save in My Library Free Full Text Gilead Sciences, Inc.announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing...
|
|
|
Gilead obtains European positive opinion for cystic fibrosis drug
(Datamonitor via COMTEX) -- GILD | Quote | Chart | News | PowerRating -- Gilead Sciences, a biopharmaceutical company, has reported that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines...
|
|
|
European CHMP Adopts Positive Opinion For Aztreonam Lysine
Gilead Sciences, Inc.(Nasdaq:GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing...
|
|
|
CHMP gives positive opinion on Gilead's MAA for aztreonam
Gilead Sciences, Inc announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing Authorisation Application for...
|
|
|
Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment of Pseudomonas Lung Infections MONMOUTH JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic...
|
|
|
Medical News: European Researchers Look For New Ways To Fight Multi-Drug-Resistant Bacterial Infections
MRSA / Drug Resistance News Main Category: MRSA / Drug Resistance Also Included In: Infectious Diseases / Bacteria / Viruses email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public:...
|
|
|
European Researchers Look For New Ways To Fight Multi-Drug-Resistant Bacterial Infections
The Institute of Biotechnology and Biomedicine (IBB) belonging to Universitat Autnoma de Barcelona (UAB) is directing the AntiPathoGN European research project aimed at looking for new drug targets in pathogenic bacteria resistant to...
|
|
|
European Researchers Look For New Ways To Fight Multi-Drug-Resistant Bacterial Infections
The Institute of Biotechnology and Biomedicine (IBB) belonging to Universitat Autnoma de Barcelona (UAB) is directing the AntiPathoGN European research project aimed at looking for new drug targets in pathogenic bacteria resistant to...
|
|
|
European CHMP Adopts Positive Opinion for Aztreonam Lysine
FOSTER CITY, Calif.-- (BUSINESS WIRE) -- Gilead Sciences, Inc.(Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive...
|
|
|
Committee For Medicinal Products For Human Use Summary Of Positive Opinion For Cayston
International Nonproprietary Name (INN): aztreonam LONDON, June 25, 2009-On 25 June 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion,** recommending to grant a conditional marketing authorisation for...
|
|
|
Committee For Medicinal Products For Human Use Summary Of Positive Opinion For Cayston
International Nonproprietary Name (INN): aztreonam LONDON, June 25, 2009-On 25 June 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion,** recommending to grant a conditional marketing authorisation for...
|
|
|
European CHMP Adopts Positive Opinion for Aztreonam Lysine
- Gilead Sciences, Inc.(Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the companys Marketing...
|
|
|
European CHMP Adopts Positive Opinion for Aztreonam Lysine
Companies mentioned in this article: Gilead Sciences, Inc.FOSTER CITY, Calif. -- (BUSINESSWIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific...
|
|
|
Gilead (GILD) Announces European CHMP Adopts Positive Opinion for Aztreonam Lysine
Gilead Sciences, Inc.(Nasdaq: GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing...
|
|
|
Gilead Sciences (GILD) Announces European CHMP Positive Opinin for Aztreonam Lysine
Gilead Sciences, Inc.(Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing...
|
|
|
Gilead Sciences' Aztreonam Lysine For Cystic Fibrosis Receives Positive Opinion From European CHMP - Update
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Biopharmaceutical company Gilead Sciences, Inc.(GILD: News ) said Friday that its Marketing Authorisation Application for aztreonam lysine for cystic fibrosis received a positive opinion from...
|
|
|
European CHMP Adopts Positive Opinion for Aztreonam Lysine
iences, Inc.(Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing Authorisation...
|
|
|
European CHMP Adopts Positive Opinion for Aztreonam Lysine
Gilead Sciences, Inc.(Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the companys Marketing...
|
|
|
European CHMP Adopts Positive Opinion for Aztreonam Lysine
BusinessWire - Gilead Sciences, Inc.(Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's...
|
|
|
Gilead Sciences Says European CHMP Adopts Positive Opinion For Aztreonam Lysine - Quick Facts
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Gilead Sciences Inc.(GILD: News ) announced that the Committee for Medicinal Products for Human Use or CHMP, the scientific committee of the European Medicines Agency, has adopted a positive...
|
